S

    SSKN (SSKN)

    Official site

    MEDICAL DEVICES

    $0.01
    +0.00 (+0.00%)

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(21/37)
    Avg Surprise
    -191.88%

    Upcoming Estimates

    Period ending Mar 31, 2026
    EPS Consensus$-0.36
    Range$-0.36 - $-0.36
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.32+11.1%
    60d ago$-0.32+11.1%
    30d ago$-0.32+11.1%
    7d ago$-0.32+11.1%
    Current$-0.36
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-$-0.36---
    Sep 25
    Reported Nov 13
    		$-0.36$0.03-1300.00%Miss+30.9%
    Jun 25
    Reported Aug 13
    		$-0.60$0.01-6100.00%Miss-1900.0%
    Mar 25
    Reported May 14
    		$-0.58$-0.56-3.57%Miss-480.0%
    Dec 24
    Reported Mar 27
    		$0.29$-0.40+171.80%Beat+361.1%
    Sep 24
    Reported Nov 13
    		$-0.52$-0.44-18.34%Miss-1635.7%
    Jun 24
    Reported Aug 14
    		$-0.03N/A+95.71%Beat+50.0%
    Mar 24
    Reported May 15
    		$-0.10$-0.07-42.86%Miss-25.0%
    Dec 23
    Reported Mar 27
    		$-0.11$-0.02-450.00%Miss-344.4%
    Sep 23
    Reported Nov 14
    		$-0.03$-0.04+25.00%Beat+0.0%
    Jun 23
    Reported Aug 9
    		$-0.06$-0.05-20.00%Miss-20.0%
    Mar 23
    Reported May 15
    		$-0.08$-0.07-14.29%Miss-14.3%
    Dec 22
    Reported Mar 31
    		$0.04$-0.05+190.00%Beat+325.0%
    Sep 22
    Reported Nov 9
    		$-0.03$-0.06+50.00%Beat-50.0%
    Jun 22
    Reported Aug 10
    		$-0.05$-0.05+0.00%Beat-266.7%
    Mar 22
    Reported May 11
    		$-0.07$-0.06-16.67%Miss+0.0%
    Dec 21
    Reported Mar 21
    		$-0.02$-0.02+0.00%Beat-100.0%
    Sep 21
    Reported Nov 10
    		$-0.02N/A+60.00%Beat+50.0%
    Jun 21
    Reported Aug 16
    		$0.03$-0.04+175.00%Beat+160.0%
    Mar 21
    Reported May 12
    		$-0.07$-0.04-75.00%Miss-133.3%
    Dec 20
    Reported Mar 24
    		$-0.01N/A+66.67%Beat-212.4%
    Sep 20
    Reported Nov 10
    		$-0.04$-0.04+0.00%Beat-33.3%
    Jun 20
    Reported Aug 11
    		$-0.05$-0.03-66.67%Miss-66.7%
    Mar 20
    Reported May 12
    		$-0.03$-0.05+40.00%Beat-50.0%
    Dec 19
    Reported Mar 17
    		$0.01N/A+144.50%Beat+278.0%
    Sep 19
    Reported Oct 30
    		$-0.03$-0.01-200.00%Miss-200.0%
    Jun 19
    Reported Aug 13
    		$-0.03$-0.01-200.00%Miss-50.0%
    Mar 19
    Reported May 14
    		$-0.02$-0.03+33.33%Beat-122.2%
    Dec 18
    Reported Mar 23
    		$-0.01$-0.01+50.00%Beat-105.6%
    Sep 18
    Reported Nov 13
    		$-0.01N/A+75.00%Beat+98.7%
    Jun 18
    Reported Aug 13
    		$-0.02$-0.03+33.33%Beat+96.2%
    Mar 18
    Reported Apr 2
    		$0.09N/A+110.00%Beat+108.7%
    Dec 17
    Reported Dec 31
    		$0.09N/A+110.00%Beat+122.5%
    Sep 17
    Reported Nov 9
    		$-0.75$-0.68-10.29%Miss-7.1%
    Jun 17
    Reported Aug 10
    		$-0.52$-0.71+26.76%Beat-
    Mar 17
    Reported May 11
    		$-1.03$-0.75-37.33%Miss-
    Dec 16
    Reported Mar 9
    		$-0.40$-0.65+38.46%Beat-
    Sep 16
    Reported Nov 10
    		$-0.70$-0.50-40.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.00EV/EBITDAN/A
    Price/FCF-0.01xFCF Yield-14890.80%
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROIC-20.34%
    Financial Health
    Debt/Equity5.28xInterest Coverage-2.40x
    Current Ratio0.58xQuick Ratio0.48x
    Trading Statistics
    BetaN/AAvg Volume2.49K
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.00
    SMA 20$0.00
    SMA 50$0.03
    SMA 200$0.51
    EMA 10$0.00
    EMA 20$0.01
    EMA 50$0.04
    EMA 200$0.52

    MACD

    Line: -0.01Signal: -0.01Hist: 0.00

    ADX

    ADX: 30.6+DI: 33.3-DI: 44.6

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down40.0
    PSAR$0.01

    Bollinger Bands

    Upper Band$0.01
    Lower Band$-0.00
    %B Position53290%(Upper)
    Band Width0.81

    RSI (14-Day)

    Neutral
    37.8

    Momentum Oscillators

    Stoch %K100.0
    Stoch %D89.1
    Williams %RN/A
    ROC (10d)4900.0%
    Momentum0.00
    CCI (20d)95.7
    MFI (14d)16.6

    Volatility Measures

    ATR (14d)$0.00(43.4%)
    StdDev (20d)0.00
    Hist VolN/A

    Volume Flow

    VWAP$0.01
    OBV264.2M
    AD Line-73.5M
    CMF (20d)0.049

    Volume Metrics

    Avg Vol (20d)2.4K
    Vol Ratio0.8x
    VWMA (20d)$0.00

    Pivot Points

    R3$0.01
    R2$0.01
    R1$0.01
    Pivot Point$0.01
    S1$0.01
    S2$0.01
    S3$0.01

    Advanced Oscillators

    TSI-39.24
    Ultimate Osc91.3
    KSTN/A

    Financial Data

    QuarterDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total Revenue$9.29M$6.93M$7.66M$6.81M$9.58M$8.80M$8.44M$6.75M$8.69M$8.85M$8.25M$7.57M
    Cost of Revenue$3.55M$2.75M$3.36M$3.17M$3.70M$3.51M$3.46M$3.67M$3.89M$3.90M$3.93M$3.18M
    Gross Profit$5.74M$4.18M$4.31M$3.65M$5.88M$5.29M$4.98M$3.08M$4.80M$4.95M$4.32M$4.39M
    Operating Expenses$5.03M$5.36M$6.53M$5.66M$10.15M$6.89M$5.46M$5.97M$8.24M$5.57M$6.28M$6.97M
    R&D$67,000$172,000$86,000$96,000$200,000$243,000$199,000$241,000$380,000$248,000$374,000$315,000
    SG&A$2.03M$2.67M$2.91M$2.57M$2.35M$3.62M$2.21M$2.71M$2.82M$2.28M$2.49M$2.92M
    Operating Income$712,000$-1,173,000$-2,224,000$-2,015,000$-4,275,000$-1,605,000$-486,000$-2,889,000$-3,441,000$-615,000$-1,962,000$-2,586,000
    Interest Income$66,000$49,000$226,000$69,000$75,000$68,000$54,000$45,000$83,000$90,000$21,000$37,000
    Interest Expense$484,000$498,000$491,000$486,000$515,000$537,000$531,000$524,000$528,000$528,000$1.21M$286,000
    Income Before Tax$294,000$-1,622,000$-2,489,000$-2,432,000$-4,715,000$-2,074,000$-99,000$-3,368,000$-3,886,000$-1,053,000$-3,148,000$-2,835,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$282,000$-1,622,000$-2,489,000$-2,432,000$-4,545,000$-2,074,000$-99,000$-3,368,000$-3,794,000$-1,053,000$-3,148,000$-2,835,000
    EBITDA$1.92M$-441,000$-880,000$-671,000$-2,922,000$-246,000$1.75M$-1,514,000$-2,042,000$952,000$-429,000$-1,043,000
    EBIT$712,000$-1,173,000$-2,224,000$-2,015,000$-4,275,000$-1,605,000$378,000$-2,889,000$-3,441,000$-615,000$-1,962,000$-2,586,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SSKN

    News

    Strata Skin Sciences, Inc. Revenue Breakdown – OTC:SSKN

    Strata Skin Sciences, Inc. (OTC: SSKN) reported that the United States was its primary revenue contributor, generating $20.58 million USD last year, a slight decrease from $20.89 million USD the preceding year. This financial breakdown highlights the company's regional performance and its main source of income.

    TradingView•8/1/26•
    Neutral

    Dermatology Industry Movers & Shakers: The Latest C-suite Appointments, Promotions, and Leadership Changes

    This article details recent executive appointments and leadership changes within the dermatology industry. Erica Jordan has been appointed as the new CEO of STRATA Skin Sciences, focusing on scaling commercial operations. Pia Renaudin is stepping down as CEO of SciBase by the end of 2026, with the company initiating a search for her successor while maintaining its US market strategy. Additionally, Hannah Mack has been promoted to Product Director, Dermatology, at Castle Biosciences, Inc.

    The Dermatology Digest•7/29/26•
    Bullish

    Press Release: STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer

    STRATA Skin Sciences has appointed Erica Jordan as its new Chief Executive Officer, effective July 29, 2026. Jordan brings over 20 years of experience in the aesthetics and medical device industries, including notable leadership roles at Cynosure, Cutera, and Lumenis. The company anticipates her leadership will drive continued growth and innovation, particularly with its XTRAC and TheraClear X products.

    Moomoo•7/28/26•
    Bullish

    STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer

    STRATA Skin Sciences has appointed Erica Jordan as its new Chief Executive Officer, effective July 12, 2026. Jordan, a medical device commercial leader with a strong background in sales expansion and market transformation, is expected to lead STRATA into its next phase of growth by scaling its commercial organization. The company, known for its innovative products for dermatologic conditions, aims to increase patient access to its therapies under her leadership.

    GlobeNewswire•7/28/26•
    Bullish

    STRATA's New CEO Targets Wider Access to Laser Therapies

    STRATA Skin Sciences (SSKN) has appointed Erica Jordan as its new CEO, effective July 12, 2026. Jordan, a seasoned medical device commercial leader, is tasked with scaling STRATA's commercial organization to broaden provider and patient access to excimer laser therapies for dermatologic conditions. Her strategic focus includes leveraging proven clinical outcomes and an asset-light partnership model to drive market leadership and continued revenue growth.

    Stock Titan•7/28/26•
    Bullish

    Frequently Asked Questions About SSKN

    Does SSKN pay dividends?
    SSKN (SSKN) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In